Today’s Price Action: Could Alder Biopharmaceuticals Inc Rise Even More? The Stock Had Another Big Increase Today

Today's Price Action: Could Alder Biopharmaceuticals Inc Rise Even More? The Stock Had Another Big Increase Today

The stock of Alder Biopharmaceuticals Inc (NASDAQ:ALDR) is a huge mover today! The stock increased 4.73% or $1.48 during the last trading session, hitting $32.77. About 668,026 shares traded hands or 16.23% up from the average. Alder Biopharmaceuticals Inc (NASDAQ:ALDR) has risen 60.54% since February 26, 2016 and is uptrending. It has outperformed by 50.12% the S&P500.
The move comes after 5 months positive chart setup for the $1.54B company. It was reported on Oct, 1 by Barchart.com. We have $43.91 PT which if reached, will make NASDAQ:ALDR worth $523.60 million more.

Analysts await Alder Biopharmaceuticals Inc (NASDAQ:ALDR) to report earnings on November, 3. They expect $-0.83 earnings per share, down 33.87% or $0.21 from last year’s $-0.62 per share. After $-0.79 actual earnings per share reported by Alder Biopharmaceuticals Inc for the previous quarter, Wall Street now forecasts 5.06% negative EPS growth.

Alder Biopharmaceuticals Inc (NASDAQ:ALDR) Ratings Coverage

Out of 6 analysts covering Alder Biopharmaceuticals (NASDAQ:ALDR), 6 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Alder Biopharmaceuticals has been the topic of 8 analyst reports since August 6, 2015 according to StockzIntelligence Inc. The rating was maintained by Credit Suisse on Tuesday, March 29 with “Outperform”. Brean Capital initiated the shares of ALDR in a report on Wednesday, April 20 with “Buy” rating. On Wednesday, July 27 the stock rating was maintained by Jefferies with “Buy”. Jefferies initiated it with “Buy” rating and $72 target price in Wednesday, September 9 report. The stock of Alder Biopharmaceuticals Inc (NASDAQ:ALDR) earned “Outperform” rating by Wells Fargo on Thursday, April 21. JP Morgan initiated Alder Biopharmaceuticals Inc (NASDAQ:ALDR) on Tuesday, September 13 with “Overweight” rating.

According to Zacks Investment Research, “Alder Biopharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and seeks to commercialize therapeutic antibodies. It is developing monoclonal antibodies comprising ALD403, for the prevention of migraine; and Clazakizumab, in the treatment of rheumatoid arthritis and psoriatic arthritis. Alder Biopharmaceuticals Inc. is headquartered in Bothell, Washington.”

Another recent and important Alder Biopharmaceuticals Inc (NASDAQ:ALDR) news was published by Fool.com which published an article titled: “Why Alder Biopharmaceuticals Is Sky-Rocketing Today” on March 28, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment